Carregant...

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Abstract Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs may rarely cause immune-related infectious complications, including re-activation of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, John M. Kirkwood, Helen Gogas
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019-09-01
Col·lecció:Journal for ImmunoTherapy of Cancer
Matèries:
Accés en línia:http://link.springer.com/article/10.1186/s40425-019-0717-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!